Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : CRDF save search
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.85%
H: 5.73%
C: -4.55%
ongoing preclinical meeting study
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 1.54%
H: 4.3%
C: -11.14%
meeting
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
business year update results
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
crdf-004 first cancer trial
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
update trial
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 1.19%
H: 1.76%
C: -0.59%
report business year update results
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
Published: 2024-01-17 (Crawled : 15:30) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: -2.45%
H: 2.52%
C: -7.55%
cancer publication research study
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-20 (Crawled : 21:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.0%
H: 1.72%
C: -0.86%
conference
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
Published: 2023-10-26 (Crawled : 20:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.63%
H: 5.11%
C: 1.3%
report business update financial results
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Published: 2023-09-26 (Crawled : 20:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 17.9%
H: 4.97%
C: -16.23%
lung positive onvansertib cancer pancreatic cell
Cardiff Oncology to Present at Upcoming Investor Conferences - September 5, 2023
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.54%
H: 1.08%
C: -2.69%
Cardiff Oncology to Present at Upcoming Investor Conferences in September
Published: 2023-09-05 (Crawled : 12:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.54%
H: 1.08%
C: -2.69%
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
Published: 2023-08-09 (Crawled : 20:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 9.95%
H: 4.29%
C: -1.43%
business update results
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
Published: 2023-08-07 (Crawled : 20:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 6.37%
H: 67.07%
C: 30.54%
cancer program
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-07-24 (Crawled : 21:00) - prnewswire.com
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: -0.67%
H: 2.03%
C: -2.7%
nasdaq grant
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
Published: 2023-03-28 (Crawled : 14:00) - biospace.com/
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 1.37%
H: 4.72%
C: 2.7%
onvansertib cancer trial phase 2
Cardiff Oncology Formally Introduces Scientific Advisory Board
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.47%
H: 1.04%
C: 0.64%
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 1.14%
H: 0.0%
C: -3.37%
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Published: 2023-03-02 (Crawled : 22:00) - biospace.com/
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.76%
H: 1.45%
C: 1.05%
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.58%
H: 1.16%
C: 0.0%
year update results
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 1.22%
H: 2.41%
C: -1.2%
care conference health
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Published: 2023-02-02 (Crawled : 14:20) - biospace.com/
CRDF | $4.36 0.23% -0.23% 410K
|
Health Services
|
| O: 0.58%
H: 3.49%
C: 1.74%
medical
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.